HLA
CHRS icon

Hamilton Lane Advisors’s Coherus Oncology CHRS Stock Holding History

Hamilton Lane Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-9,399
Closed -$265K – 60
2016
Q4 		$265K Hold
9,399
– – 0.17% 55
2016
Q3 		$252K Buy
+9,399
New +$256K 0.13% 56

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Hamilton Lane Advisors's CHRS Position: Q1 2017 in Review

Hamilton Lane Advisors sold out of Coherus Oncology (CHRS) in Q1 2017, closing a stake of 9,399 shares — an estimated $265K sold.

Hamilton Lane Advisors first reported a position in CHRS in Q3 2016 and held it in 2 quarters. The position peaked at $265K in Q4 2016. 109 funds tracked by Wall St. Rank hold CHRS as of Q1 2017.

  • Hamilton Lane Advisors reported no remaining Coherus Oncology position as of Q1 2017 after selling out during the quarter.
  • Hamilton Lane Advisors sold 9,399 Coherus Oncology shares in Q1 2017, an estimated $265K.
  • Hamilton Lane Advisors first reported a position in Coherus Oncology in Q3 2016 and held it in 2 quarters.
  • Hamilton Lane Advisors's Coherus Oncology position peaked at $265K in Q4 2016.
  • 109 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2017.

Based on Hamilton Lane Advisors's 13F filing for Q1 2017, filed 24 Apr 2017.